iCell Cardiomyocytes, 11713

Kit Size

Catalog #: R1105
Catalog #: R1117
Catalog #: R1106

Cells Only

Catalog #: C1105
Catalog #: C1106
Catalog #: C1106

Cardiomyocytes differentiated from human iPS cells, frozen

From
$595.00
Catalog # GCMC11713

Product Overview

Heart disease encompasses a wide range of conditions that can be a result of genetics, physiologic, and metabolic disorders as well as adverse drug reactions. The availability of human cell models that could be used to interrogate these various factors would have a profound impact on the effort to find new medicines and cures for heart disease. Derived from induced pluripotent stem cells (iPSCs), iCell® Cardiomyocytes from FUJIFILM Cellular Dynamics, Inc. (FCDI), enable a wide range of applications spanning disease research, drug discovery, safety and toxicity testing, and regenerative medicine.

  • Industry Standard With the most peer-reviewed publications and supported application protocols, iCell Cardiomyocytes are the in vitro model of choice.
  • Reproducible Research High purity and rigorous quality control ensure the same performance and reproducible results with every batch of iCell Cardiomyocytes.
  • Human Relevance iCell Cardiomyocytes recapitulate healthy human cardiac biology and function and express relevant targets and pathways for heart disease research.
  • Diverse Availability iCell Cardiomyocytes are now available from two backgrounds with no known disease-related genotypes: donors 01434 and 11713. Also available are cardiomyocytes generated from diseased backgrounds and engineered genotypes, including MyCell® Cardiomyocytes (R403Q), a model of hypertrophic cardiomyopathy derived from donor 01178 with genotype MYH7 R403Q.

Components:

Need Help With This Product?

Our specialists are here to help you find the best product for your application.

Our regular business hours are 9:00am to 5:00pm Central Time (USA)

Need Help With This Product?

Our specialists are here to help you find the best product for your application.

Our regular business hours are 9:00am to 5:00pm Central Time (USA)

Technical Docs

PROTOCOLS

Performance Data

Formation of 3D Cardiac Tri-Culture Microtissues

Three-dimensional multi-cellular systems containing iCell Cardiomyocytes or iCell Cardiomyocytes2, iCell Endothelial Cells and primary cardiac fibroblasts have the potential for greater physiological relevance, predictive power, and mechanistic insight than cardiomyocytes alone. For information on 3D systems, see the Application Protocol: Culturing and Assaying Calcium Transients of 3D Cardiac Tri-Culture Microtissues

Figure 1: Structure of 3D Cardiac Tri-culture Microtissues Over Time.
Microtissues were formed containing 5,000 or 10,000 total cells in S-bio 96-well plates. Compact, contracting microtissues were obtained by Day 4. (A) Panel of phase contrast 10X images of 5,000 cell tri-culture spheroids over time using the Incucyte S3. (B) Quantification of 5,000 cell tri-culture microtissue diameter. Each dot represents a microtissue. Mean and SEM are indicated. (C) Comparison of Day 14 microtissue diameter of 5,000 cell tri-culture microtissues with 10,000 cell tri-culture microtissues. Each dot represents a microtissue. Mean and SEM are indicated. (D) H&E staining of Day 14, 3D cardiac tri-culture microtissue formed with 10,000 total cells. Staining shows the absence of a necrotic core.

Figure 2: 3D Cardiac Tri-culture Microtissues Response to Beta Adrenergic Agonist Isoproterenol
(A) Chronotropic response: Control iCell Cardiomyocytes, 11713 only microtissues (CM) and tri-culture microtissues exhibit an increase in beat rate with increasing concentrations of isoproterenol. (B) Inotropic response: Control iCell Cardiomyocytes, 11713 only microtissues (CM) do not increase amplitude with increasing concentrations of isoproterenol. Tri-culture microtissues demonstrate a twofold increase in beat amplitude with increasing concentrations of isoproterenol.

Enhanced Inotropic Response when Plated in Tri-Culture

3D cardiac tri-culture microtissues containing iCell Cardiomyocytes or iCell Cardiomyocytes2, iCell Endothelial Cells and cardiac fibroblasts demonstrated a positive response to the inotropic compound isoproterenol, which is characteristic of mature cardiomyocytes. For information on 3D triculture systems, see the Application Protocol: Culturing and Assaying Calcium Transients of 3D Cardiac Tri-Culture Microtissues

Compatible with High-Sensitivity Detection of Calcium Transients in Tri-Culture

Three-dimensional multi-cellular systems containing iCell Cardiomyocytes or iCell Cardiomyocytes2, iCell Endothelial Cells and cardiac fibroblasts demonstrate enhanced amplitude in calcium transient assays. For information on 3D systems, see the Application Protocol: Culturing and Assaying Calcium Transients of 3D Cardiac Tri-Culture Microtissues

Figure 3: Baseline Calcium Transients in Cardiomyocyte and Tri-culture Microtissues at Day 14
Calcium transients were measured using EarlyTox calcium dye. (A) Representative calcium traces for 5,000 and 10,000 total cell 3D Tri-culture cardiac microtissues. (B) Beat rate is not different between 5,000 or 10,000 cell triculture microtissues and control cardiomyocyte only microtissues. (C) Representative calcium traces for 5,000 cell tri-culture and 5,000 cell cardiomyocytes only microtissues (CM only). (C) Amplitude is significantly higher in triculture microtissue compared to cardiomyocyte only microtissues (CM only) at 5,000 cells, but similar at 10,000 cells

Figure 4: iCell Cardiomyocytes are a High-Purity Cardiac Population.

iCell Cardiomyocytes are a High-Purity Cardiac Population

Flow cytometry analysis and immunostaining show that iCell Cardiomyocytes are typically >95% cTNT+) with intact sarcomeric myofilament organization. (Data were adapted from Kattman et al., 2011).

iCell Cardiomyocytes Recapitulate Native Cardiac Function

iCell Cardiomyocytes form a spontaneously beating monolayer within 7 days. iCell Cardiomyocytes contain the expected human cardiac ionic currents and show the expected effects when exposed to compounds including ion channel blockers. (Data were adapted from Ma et al., 2011).

Figure 5: iCell Cardiomyocytes Recapitulate Native Cardiac Function.

Figure 6: iCell Cardiomyocytes have Appropriate Sarcomeric Organization, Calcium Handling and Intact Excitation-Contraction Coupling.

iCell Cardiomyocytes have Appropriate Sarcomeric Organization, Calcium Handling and Intact Excitation-Contraction Coupling

Their electrophysiological activity can be pharmacologically modulated and quantified by recording the electrical activity using a multielectrode array (MEA). The field potential duration (FPD) increases or decreases as expected when exposed to ion channel-blocking drugs for key cardiac channels.

Intracellular Calcium (Ca2+) Handling Provides a High-throughput Biomarker for Ion Channel and GPCR Activity

Electrical activity at the membrane is controlled by ion channels and GPCRs. This activity drives intracellular Ca2+ handling. Panel A shows representative calcium handling waveforms at baseline. Panels B and C show the effect of the GPCR β-adrenergic agonist ISO or the IKr channel blocker E-4031, respectively.

Figure 7: Intracellular Calcium (Ca2+) Handling Provides a High-throughput Biomarker for Ion Channel and GPCR Activity.

Product Highlights

Regenerative Medicine

iCell Cardiomyocytes are compatible with bioengineered, implantable scaffolds used as a model for heart repair following myocardial infarction (Richards et al., 2017, Beauchamp et al., 2015, Holt-Casper et al., 2015, Lancaster et al., 2012).

Calcium Signaling

Simultaneously assess effects on electrical and calcium signals measurements using iCell Cardiomyocytes with FDSS ( Bedut et al., 2016) or FLIPR platforms.

Cardiac Hypertrophy Studies

iCell Cardiomyocytes can detect known and novel biomarkers and identify new targets for drug discovery and therapeutics research (Jones et al., 2015, Drawnel et al., 2014, Arrarwal et al., 2014, Traister et al., 2014, Zhi et al., 2012).

Arrhythmia Testing

iCell Cardiomyocytes are changing regulatory paradigms by providing a highly predictive model for detecting drug-induced arrhythmia (Guo et al., 2018).

Cardiotoxicity Assessment

Retrospective analyses were leveraged to uncover previously undetected mechanisms of drug-induced cardiotoxicity and provide relevant data in support of Investigational New Drug (IND) applications (Talbert et al., 2014, Cameron et al., 2013, Doherty et al., 2013, Rana et al., 2012, Cohen et al., 2011).

Publications